Objective
Blood-based biomarkers such as Circulating Tumor Cells (CTCs), circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) have the potential to improve the development of personalized medicines for cancer patients. This is of particular importance when biopsies of the primary tumor or metastases are not accessible (e.g. at early disease stages or in minimal residual disease) or possible and the associated risk of adverse events when taking a biopsy is high. Furthermore, a longitudinal follow-up of disease markers is desirable to improve prognosis or to monitor treatment efficacy. CANCER-ID aims to validate technologies for CTCs, cfDNA and miRNAs to determine the absence/presence of drug targets and assess the response to treatment.
Important challenges for all circulating biomarker development are assay sensitivity, specificity and assay standardization and validation. In three project phases (pre-evaluation, technical assay validation and clinical validation) the CANCER-ID consortium aims at the development and validation of Standard Operating Procedures (SOPs) for technologies assessing blood-based biomarkers. In the pre-evaluation phase, four working groups will be established that will evaluate biomarker technologies and set the criteria to be met for any technology before moving to the next phase. In the Technical Evaluation Phase, the technologies identified as promising in the pre-evaluation phase will be implemented and tested at the sites of the consortium members using blood samples taken from patients with metastatic carcinomas and healthy controls.
In order to prove broader applicability and clinical utility of the consortium’s technologies and protocols, the validated assays will be deployed in controlled clinical studies (TRACERx, NVALT-17, SPECTAlung; patients under SoC treatment) in 1) Non-Small Cell Lung Cancer (NSCLC) and 2) anti-Her2-resistant metastatic breast cancer (Her2RMBC). The two indications were chosen based on medical need and economic impact, technical considerations and access to clinical samples.
The combination of 17 academic groups (ten large clinical trialsites), 6 EFPIA companies with extensive experience in the use of blood-based biomarkers in clinical trials, 5 SMEs with unique technologies for CTC isolation (Vycap, Leukocare, Gilupi) or for creation of databases, analysis of complex molecular information and data management (Alacris, TATAA) and two non-profit organizations (IBBL, a Biobank with extensive experience in the validation and execution of plasma assays; EORTC, the European organization that aims to develop, conduct, coordinate, and stimulate translational and clinical research) comprises a unique network of experts in the fields of tumour biology, biomarker development, clinical sciences and bioinformatics. In addition, regulatory agencies and patient advocacy groups are involved from the beginning of the project.
The academic leaders of this consortium, Klaus Pantel, who published more than 300 reports and high impact review articles on disseminating tumor cells, and Leon Terstappen, leader of the FDA-approved benchmark CellSearch CTC detection system, are the pioneers of this field. In addition, both have extensive experience with coordination of EU projects in the field (Pantel: DISMAL, CTC-SCAN; Terstappen: CTCTrap). This is complemented by the IMI and FP7 project management experience of the EFPIA project coordinator, Thomas Schlange (Bayer Pharma AG). He will be supported by Barbara Baggiani from Menarini/Silicon Biosystems (developer and vendor of the DEPArray).
Fields of science
- natural sciencesbiological sciencesbiochemistrybiomoleculesnucleic acids
- medical and health sciencesclinical medicineoncologylung cancer
- medical and health sciencesclinical medicineoncologybreast cancer
- medical and health scienceshealth sciencespersonalized medicine
- natural scienceschemical sciencesinorganic chemistrymetalloids
Call for proposal
IMI-JU-11-2013
See other projects for this call
Coordinator
51373 Leverkusen
Germany
See on map
Participants (38)
20251 Hamburg
See on map
7522 NB Enschede
See on map
M13 9PL Manchester
See on map
94805 Villejuif
See on map
9713 GZ Groningen
See on map
40225 Dusseldorf
See on map
35128 Padova
See on map
8010 Graz
See on map
10561 Athina
See on map
34090 MONTPELLIER
See on map
CB2 1TN Cambridge
See on map
80539 Munchen
See on map
10124 Torino
See on map
10117 Berlin
See on map
0450 Oslo
See on map
69120 Heidelberg
See on map
75231 Paris
See on map
1200 Bruxelles / Brussel
See on map
1445 Strassen
See on map
14476 Postdam
See on map
7425PG Deventer
See on map
Participation ended
82152 Martinsried/Munich
See on map
412 51 GOTEBORG
See on map
12489 Berlin
See on map
Participation ended
80333 Muenchen
See on map
55218 Ingelheim
See on map
91190 GIF-SUR-YVETTE
See on map
RG21 4FA Basingstoke
See on map
02200 Espoo
See on map
40013 Castel Maggiore Bo
See on map
35041 Marburg
See on map
40724 Hilden
See on map
1930 Zaventem
See on map
GU2 7AF Guildford
See on map
76337 Waldbronn
See on map
75008 Paris
See on map
118257 Singapore
See on map
00029 Helsinki
See on map